[stock_market_widget type="clock-markets" template="analog" timezone="America/New_York" title="New York" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Europe/London" title="London" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Europe/Brussels" title="Brussels" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Asia/Hong_Kong" title="Hong Kong" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Asia/Tokyo" title="Tokyo" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Australia/Sydney" title="Sydney" style="font-size: 7px; width: 100px;"]

Stock Market News

Pfizer to buy 8.1% of capital of vaccines company Valneva

06/20/2022

Less than a minute

2022.06.20 08:36

2/2
Pfizer to buy 8.1% of capital of vaccines company Valneva
FILE PHOTO: A person walks past a Pfizer logo amid the coronavirus disease (COVID-19) pandemic in the Manhattan borough of New York City, New York, U.S., April 1, 2021. REUTERS/Carlo Allegri

2/2

PARIS (Reuters) – French specialty vaccine company Valneva and U.S. healthcare giant Pfizer (NYSE:PFE) said they had entered an equity subscription agreement under which Pfizer will invest 90.5 million euros ($95.24 million) in Valneva, representing 8.1% of its capital.

The deal comes through a reserved capital increase to further support the strategic Lyme partnership between the two companies, they added in a statement.

($1 = 0.9502 euros)

Source

06/20/2022

Less than a minute